Yukon signs first cannabis supply agreement
The Yukon Liquor Corporation has signed an agreement with Tilray Canada to supply the territory with an array of non-medical cannabis products in light of the anticipated legalization of recreational use later this year.
April 16, 2018 By Grow Opportunity staff
According to a Canadian Press report, the Nanaimo, B.C.-based cannabis producer will supply about 350 kilograms of cannabis to the liquor corporation in the first year. Yukon’s cannabis market ranges between 800 and 1,000 kilograms per year.
In a statement, Tilray said it will fulfill the agreement through its affiliate High Park Company, which was formed to produce and distribute a broad-based portfolio of adult-use cannabis brands and products.
“We are proud that the Yukon Liquor Corporation has selected us as a supplier for the territory,” said Adine Fabiani-Carter, chief marketing officer at High Park. “Our goal is to deliver on the high expectations that Canadians have of us by cultivating and distributing a portfolio of world-class adult-use products that will lead the market in quality, excellence and craftsmanship.”
The supply agreement secures a safe, regulated supply of cannabis products to Yukon from High Park. Tilray is an internationally recognized, federally licensed producer of medical cannabis “trusted for its commitment to quality, compliance and responsibility,” according to the company.
“As we prepare for the legalization of cannabis, we are pleased to announce this supply agreement with High Park as one of our main licensed producers,” Minister Responsible for the Yukon Liquor Corporation, John Streicker, said.
Under the terms of the agreement, Tilray will supply the corporation through High Park with a variety of new and established cannabis brands and products once the federal government legalizes non-medical consumption. Yukon will receive product under the terms outlined in the agreement. Tilray-branded medical products will continue to be sold exclusively in pharmacies and online through the Access to Cannabis for Medical Purposes Regulations, the company said.
Print this page